ebomi
Colour theme
Sign in
Insider · CIK 0001444717

Aisling Capital III LP

CIK 0001444717 Name as filed on the most recent filing

Filed as Aisling Capital III LP (20)

22 transaction lines · from 20 filings · filed 2011-10-25 to 2018-07-12 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

0 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2018-07-10 S, Open-market sale Loxo Oncology, Inc.LOXO 251,202,000, disposed Open Form 4 filing 0000899243-18-019810
2017-12-19 S, Open-market sale Loxo Oncology, Inc.LOXO 20,125,000, disposed Open Form 4 filing 0000950142-17-002235
2017-11-22 S, Open-market sale Loxo Oncology, Inc.LOXO 37,500,000, disposed Open Form 4 filing 0000950142-17-002107
2017-01-10 P, Open-market purchase Loxo Oncology, Inc.LOXO 4,960,000, acquired Open Form 4 filing 0000950142-17-000108
2016-07-06 P, Open-market purchase Syros Pharmaceuticals, Inc.SYRS 5,000,000, acquired Open Form 4 filing 0000950142-16-004060
2016-05-17 P, Open-market purchase Loxo Oncology, Inc.LOXO 4,999,997, acquired Open Form 4 filing 0000950142-16-003763
2015-12-11 P, Open-market purchase Loxo Oncology, Inc.LOXO 5,500, acquired Open Form 4 filing 0000950142-15-002621
2015-12-09 P, Open-market purchase T2 Biosystems, Inc.TTOO 2,999,997, acquired Open Form 4 filing 0000950142-15-002576
2015-11-17 P, Open-market purchase Loxo Oncology, Inc.LOXO 7,022,500, acquired Open Form 4 filing 0000950142-15-002461
2015-11-13 P, Open-market purchase Loxo Oncology, Inc.LOXO 53,704, acquired Open Form 4 filing 0000950142-15-002434
2015-11-12 P, Open-market purchase Loxo Oncology, Inc.LOXO 2,121,319, acquired Open Form 4 filing 0000950142-15-002434
2015-01-27 P, Open-market purchase Versartis, Inc.VSAR 2,501,250, acquired Open Form 4 filing 0000950142-15-000194
2015-01-23 P, Open-market purchase Agile Therapeutics IncAGRX 4,750,001, acquired Open Form 4 filing 0000950142-15-000157
2014-08-12 P, Open-market purchase T2 Biosystems, Inc.TTOO 4,999,995, acquired Open Form 4 filing 0001104659-14-061090
2014-08-06 P, Open-market purchase Loxo Oncology, Inc.LOXO 5,370,001, acquired Open Form 4 filing 0001140361-14-031039
2014-04-21 P, Open-market purchase Transenterix Inc.TRXC 4,151,068, acquired Open Form 4 filing 0000950142-14-000941
2014-03-26 P, Open-market purchase Versartis, Inc.VSAR 1,260,000, acquired Open Form 4 filing 0001209191-14-023549
2014-03-21 S, Open-market sale Durata Therapeutics, Inc.DRTX 41,255, disposed Open Form 4 filing 0000950142-14-000705
2014-03-20 S, Open-market sale Durata Therapeutics, Inc.DRTX 1,542,589, disposed Open Form 4 filing 0000950142-14-000705
2013-11-14 S, Open-market sale Zeltiq Aesthetics IncZLTQ 7,026,500, disposed Open Form 4 filing 0000950142-13-002267
2012-07-24 P, Open-market purchase Durata Therapeutics, Inc.DRTX 9,999,999, acquired Open Form 4 filing 0000950142-12-001608
2011-10-24 P, Open-market purchase Zeltiq Aesthetics IncZLTQ 10,000,003, acquired Open Form 4 filing 0001181431-11-053467

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Search the catalog
Codes on this page
S, Open-market sale
Open-market sale
P, Open-market purchase
Open-market purchase

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens.

What this insider's stored lines contain

No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.

How to cite this page

ebomi catalog. AISLING CAPITAL III LP, insider transactions. Retrieved 2026-08-22 from https://ebomi.com/insider/0001444717

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.